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Background: Previous research on serum total cholesterol and suicidality has yielded conflicting results. Several
studies have reported a link between low serum total cholesterol and suicidality, whereas others have failed to
replicate these findings, particularly in patients with major affective disorders. These discordant findings may reflect
the fact that studies often do not distinguish between patients with bipolar and unipolar depression; moreover,
definitions and classification schemes for suicide attempts in the literature vary widely.
Methods: Subjects were patients with one of the three major psychiatric disorders commonly associated with
suicide: schizophrenia, bipolar affective disorder, and major depressive disorder (MDD). We compared serum lipid
levels in patients who died by suicide (82 schizophrenia, 23 bipolar affective disorder, and 67 MDD) and non-suicide
controls (200 schizophrenia, 49 bipolar affective disorder, and 175 MDD).
Results: Serum lipid profiles did not differ between patients who died by suicide and control patients in any
diagnostic group.
Conclusions: Our results do not support the use of biological indicators such as serum total cholesterol to predict
suicide risk among patients with a major psychiatric disorder.
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Several studies have shown an association between sui-
cidal behavior and low levels of plasma total cholesterol
[1-4]. Cholesterol is essential for the cell membrane sta-
bility and neurotransmission in central nervous system
[5]. Relationship between serum cholesterol and suicidal
behavior is explained by the hypothesis that reduced
serum cholesterol level may be associated reduced cen-
tral serotonergic activity by changes in viscosity and
functions of serotonin receptors and transporters [6,7].* Correspondence: jphong@amc.seoul.kr
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reproduction in any medium, provided the orRecently, Freemantle et al. [8] compared synaptosomal
cholesterol and phospholipid levels in suicide completers
and controls and found that cholesteryl ester hydrolase
was significantly increased in people who committed
violent suicides and was associated with alterations in
brain phospholipids. However, several studies conducted
in patients with a major affective disorder have found no
significant association between serum cholesterol and
suicide [9-12].
These discordant findings may reflect the fact that
studies often do not distinguish between patients with
bipolar and unipolar depression [5]. Moreover, the defi-
nitions and classification schemes for suicide attempts
vary widely (e.g., the distinction between lethality and/or
intent to die), which may contribute to inconsistent
results across studies [13]. For example, Deisenhammer
et al. [14] found no significant difference in lipid levels. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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attempted suicide; however, the authors reported a lower
total cholesterol level in patients who committed violent
suicides compared with those who poisoned themselves.
Furthermore, association between cholesterol level and
suicidal behavior was mostly investigated in suicide
attempters rather than suicide completers [9], although
suicide completers may be a more homogeneous group
than suicide attempters [6].
In view of the limited data available in the suicide
completers with a specific psychiatric disorder, we com-
pared serum lipid metabolites including serum total
cholesterol between patients who died by suicide and
non-suicide controls in each group of three major psy-
chiatric disorders commonly associated with suicide:




Using electronic medical records, we identified all
patients who were admitted to a psychiatric ward at a
university hospital in Seoul, Korea, for schizophrenia
(N = 1562), bipolar affective disorder (N = 728), or MDD
(N = 1455) between January, 1989, to December, 2006.
All identified patients were older than 18 years of age at
the time of admission. The medical record requirements
of the participating hospital included one primary diag-
nosis and several auxiliary diagnoses based on the Inter-
national Classification of Disease, 10th edition (ICD-10)
coding in a discharge summary, which had been re-
corded by an attending board-certified psychiatrist after
close inpatient observation, neuropsychological test, and
clinical interview. The diagnosis used for individuals
with multiple psychiatric disorders was the primary
ICD-10 diagnosis provided in the electronic medical
record.
Information about whether or not the patients were
alive on December 31, 2009, was obtained from the
database of the Korea National Statistical Office. For de-
ceased patients, cause of death was also obtained from
the database of the Korea National Statistical Office. Sui-
cide decedents were identified as those with ICD-9
codes E950-E959 between 1989-1998 and those with
ICD-10 codes X60-X84 between 1999-2005. Of the
1,562 patients with schizophrenia, 84 had died by suicide
prior to December 31, 2009. Of the 728 patients with bi-
polar affective disorder, 30 had died by suicide, and of
the 1,455 patients with MDD, 72 had died by suicide
prior to December 31, 2009. Among these suicide com-
pleters, we excluded patients who lacked fasting labora-
tory values, had a substance use disorder or an eating
disorder, or took cholesterol-lowering drugs. Among 84
patients with schizophrenia, 1 had taking cholesterollowering agent, 1 had a substance use disorder. Among
30 patients with bipolar disorder, 7 patients had eating
disorder. Among 72 patients with major depressive dis-
order, 2 patients taking cholesterol lowering drug, 3 pa-
tients had a substance use disorder. The remaining 82
patients with schizophrenia, 23 patients with bipolar
affective disorder, and 67 patients with MDD formed the
study sample. As a non-suicide control group, we ran-
domly selected two age (at the time of admission) - and
sex-matched controls to each patient who were alive on
December 31, 2009. Patients with past history of suicide
attempt were excluded from control group, and other
exclusion criteria of the control group were same as the
suicidal group. Finally, the 164 patients with schizophre-
nia, 46 patients with bipolar affective disorder, and 134
patients with MDD formed the control group sample.
Three psychiatric residents reviewed the electronic
medical records and recorded socio-demographic (age at
the time of admission, sex, body mass index, and socio-
economic status) and clinical (age at first admission,
number of admissions, and history of previous suicide
attempts) characteristics. The lipid metabolites (trigly-
ceride, total cholesterol, high-density lipoprotein choles-
terol, glucose) at the time of admission were recorded.
For patients who had recurrent admission, laboratory
values of last admission were used. Atypical anti-
psychotic drug used at the time of admission was also
recorded, because it might be associated with hypertri-
glyceridemia, hypercholesterolemia, and hyperglycemia
[15].
The study was approved by the institutional review
board for human subjects at the Asan Medical Center,
Ulsan University College of Medicine.
Statistical analysis
We compared socio-demographic and clinical character-
istics and serum lipid metabolites between patients who
died by suicide and controls in each diagnostic group
using an independent t-test for continuous variables and
a chi-square test for categorical variables. All statistical
analyses were performed using SPSS (version 21.0; SPSS
Inc., Chicago, IL), with statistical significance defined as
an alpha level of 0.05
Results
Table 1 shows demographic and clinical characteristics
of participants. Schizophrenia patients who died by sui-
cide were composed of 58 paranoid type (70.7%), 3 dis-
organized type (3.7%), 1 catatonic type (1.2%), and 17
undifferentiated type (20.7%), and 3 residual type (3.7%)
and those who did not were composed of 124 paranoid
type (75.6%), 3 disorganized type (1.8%), 5 catatonic type
(3.0%), and 27undifferentiated type (16.5%) and 5 re-
sidual type (3.0%). There was no significant difference in
Table 1 Characteristics of schizophrenia, bipolar affective disorder, and major depressive disorder patients who died
by suicide and those who did not













N = 82 N = 164 N = 23 N = 46 N = 67 N = 134




31.5 ± 8.6 0.699a 36.5 ±
11.6
35.9 ± 10.0 0.830a 52.6 ±
15.2
54.1 ± 15.2 0.519a
Age at first admission (years) 29.1 ±
9.3
29.3 ± 8.9 0.859a 34.0 ±
11.6
32.7 ± 10.4 0.620a 51.6 ±
15.1
53.2 ± 14.8 0.494a
Number of admissions, mean ± SD 2.2 ± 2.3 2.4 ± 2.5 0.638a 2.5 ± 1.8 2.5 ± 2.1 >0.99a 1.6 ± 1.3 1.6 ± 1.0 0.895a
Body mass index (kg/m2), mean ± SD 22.1 ±
3.7
23.1 ± 4.1 0.086a 23.8 ± 3.6 23.9 ± 3.0 0.93a 22.8 ± 3.2 22.9 ± 3.5 0.894a
Sex, male, n (%) 42(51) 80(49) 0.787b 14(61) 29(63) >0.99b 30(45) 56(42) 0.763b
Socio-economic status, n (%) 0.479b 0.457b 0.259b
High 19(27) 33(21) 3(14) 12(27) 13(24) 39(31)
Middle 32(45) 84(53) 12(55) 22(50) 28(51) 66(53)
Low 20(28) 41(26) 7(32) 10(23) 14(25) 20(16)
Use of atypical antipsychotics, n (%) 16 (19.5) 43 (26.2) 0.245b 4 (17.4) 11 (23.9) 0.536b 4 (6.0) 7 (5.2) 0.826b
Comorbid medical disease
None 75(91.5) 155(94.5) 0.361b 17(73.9) 40(87.0) 0.178b 47(70.1) 81(60.4) 0.178b
Endocrine disease 2(2.4) 1 (0.6) 0 0 4(6.0) 13(9.7)
Cardiovascular disease 0 1(0.6) 2(8.7) 2(3.3) 12(17.9) 22(16.4)
Liver disease 0 3(1.8) 1(4.3) 0 0 3(2.2)
Neurological disease 3(3.7) 1(0.6) 2(8.7) 1(2.2) 3(4.5) 3(2.2)
Cancer 0 0 0 0 0 3(2.2)
Othersc 2(2.4) 3(1.8) 1(4.3) 3(6.5) 1(1.5) 9(6.7)
a, t-test; b, X2 test; c, Others include cystitis, fracture, rheumatoid arthritis, blind, pneumothorax, and pulmonary tuberculosis.
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who died by suicide and controls (p = 0.669). All patients
with bipolar disorder suffered from bipolar I disorder.
There were no significant differences in socio-
demographic and clinical characteristics as well as
comorbid medical disease between patients who died by
suicide and controls in any diagnostic group. Atypical
antipsychotics, known to be cause hypertriglyceridemia,
hypercholesterolemia, and hyperglycemia, were used
only in small number of patients, because most patients
were admitted when their symptoms were developed orTable 2 Lipid levels of schizophrenia, bipolar affective disord
suicide and those who did not
Schizophrenia Bipolar
Suicide Non-suicide p-value Suicide
N = 82 N = 164 N = 23
Total cholesterol(mg/dL) 162.9 ±36.1 172.3 ± 41.1 0.082 165.2 ±
Glucose (mg/dL) 94.1 ± 29.5 96.1 ± 23.9 0.567 93. 9 ±
Triglyceride (mg/dL) 104.9 ± 54.9 129.5 ± 74.2 0.124 105.9 ±
HDL cholesterol(mg/dL) 47.2 ± 17.1 48.3 ± 13.3 0.745 61.7 ± 1
Data are presented as mean ± standard deviation. P-values were determined by t-taggravated without any medication and laboratory test
were conducted before starting medication. There were
no significant differences in use of atypical antipsy-
chotics between patients who died by suicide and con-
trols in any diagnostic group.
Table 2 shows serum lipid metabolites of patients who
died by suicide and controls in each diagnostic group.
Lipid profiles did not differ between patients who died
by suicide and controls in any diagnostic group.
When we compared serum lipid metabolites across
diagnosis group, patients with MDD showed significantlyer and major depressive disorder patients who died by
affective disorder Major depressive disorder
Non-suicide p-value Suicide Non-suicide p-value
N = 46 N = 67 N = 134
30.8 167.9 ± 42.9 0.791 180.9 ± 40.0 180.6 ± 35.4 0.945
20.3 103.9 ± 27.8 0.135 108.5 ± 44.2 101.0 ± 24.5 0.202
88.6 128.1 ± 95.2 0.467 107.8 ± 57.9 131.0 ± 74.1 0.124
9.4 53.5 ± 12.5 0.165 49.5 ± 15.5 50.4 ± 15.9 0.795
est. HDL, high density lipoprotein.
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compared to patients with schizophrenia (mean = 169,2,
SD = 39.7) or bipolar affective disorders (mean = 167.0,
SD = 39.1) (F = 6.04, p = 0.003). However, after adjusting
for age, any lipid profiles did not differ between three
diagnosis group (adjusted mean ± SE = 173.2 ± 3.2for
MDD, 174.5 ± 2,8 for schizophrenia, and169.6 ± 4.6 for
bipolar affective disorder, respectively; p = 0.644).Discussion
We found no association between death by suicide and
the levels of serum lipid metabolites in our sample of in-
patients with schizophrenia, bipolar affective disorder,
and major depressive disorder (MDD). Thus, our results
do not support the use of biological indicators, such as
serum total cholesterol level, as predictors of suicide risk
in inpatients with a major psychiatric disorder.
Our findings are consistent with those of previous
studies that found no association between low serum
cholesterol levels and suicide attempts in patients with
major affective disorders. For example, Fiedorowicz et al.
[9] reported that low serum cholesterol levels did not
predict subsequent suicide attempts in a prospective
sample of inpatients with unipolar major depression, bi-
polar depression, or schizoaffective depression. Pompili
et al. [12] found no significant difference in serum chol-
esterol and triglyceride levels between patients with
major affective disorders who had been admitted for a
medically serious suicide attempt and patients who had
not made a recent suicide attempt. In contrast, Papado-
poulou et al. [16] reported that serum cholesterol levels
were lower in suicide attempters with a major affective
disorder than in healthy controls, and that serum choles-
terol levels were negatively correlated with suicide intent
scores. The authors concluded that serum cholesterol
was a biological risk factor for suicidal behavior in
affective patients. However, Papadopoulou and col-
leagues investigated suicide attempts rather than suicide
completion and did not distinguish between patients
with bipolar and unipolar depression.
In a meta-analysis of 11 large follow-up studies that
investigated the link between low serum cholesterol,
Lester et al. [4] found that lower cholesterol levels were
associated with a small, but statistically significant, in-
crease in the risk of completed suicide. Of those 11 stud-
ies, only two were conducted in individuals with mood
disorders, and no significant differences in serum choles-
terol or serum triglyceride were found between patients
with depression who committed suicide and those who
were non-suicidal [10,11]. Tsai et al. [17] also reported
that there were no significant differences in fasting levels
of serum cholesterol or blood sugar between the suicide
completers and the living controls among inpatientswith bipolar disorder in Taiwan. Our results were con-
sistent with these findings.
It is notable that patients with MDD showed signifi-
cantly higher total cholesterol levels compared to
patients with schizophrenia, bipolar affective disorders.
However, after adjusting for age, these significant differ-
ences did not remain. Therefore, higher cholesterol level
in patients with MDD might be due to their older age
than other diagnostic groups, because serum cholesterol
level generally increased, about to 60 years old [18].
The present study is limited by its small sample size
and lack of laboratory data during follow-up after dis-
charge from hospital. The small number of cases may
have reduced the likelihood of finding statistical signifi-
cance. When we conducted a power analysis (independ-
ent t-test, 1-tailed, α=0.05, β=0.80) based on previous
studies’ total cholesterol levels of suicidal patients and
psychiatric controls [17,19-21], the required sample size
to detect a significant group-differences ranged between
14 and 80 per group. Therefore, at least for schizophre-
nia group, with the given sample size (82 suicides and
164 non-suicides), it is possible to detect clinical relevant
differences and the negative finding may not come from
a small sample size. Additionally, since the study was
conducted in a single university hospital, the findings
may not be representative of all Korean patients with
major psychiatric disorders. In a university hospital set-
ting, patients with severe disease and with high suicide
risk could be over-represented and further community-
based study is therefore required. Moreover, as with
most retrospective studies, there were no standardized
procedures for arriving at diagnoses. In addition, because
data were gathered from electronic medical charts, with-
out data from face-to-face interviews, some information
on risk factors previously identified, such as symptom-
atic characteristics (i.e., self-devaluation, hopelessness,
and insomnia) and poor adherence to medications [22]
have not been available. Finally, non-significant differ-
ences in potential confounders between the suicide and
non-suicide groups (e.g., previous history of suicide
attempt) could have biased our results.
In conclusion, our results do not support the use of
biological indicators such as serum total cholesterol to
predict suicide risk among patients with a major psychi-
atric disorder. To clarify these issues, further longitu-
dinal studies on a large sample of patients are need.Consent
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